BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]
BioAtla, Inc. (BCAB)
Company Research
Source: Yahoo! Finance
trial for second-line and later (2L+) oropharyngeal squamous cell carcinoma (OPSCC). As part of transaction, BioAtla is set to receive an initial $5m from Inversagen AI, a newly established company focused on age-related disease research. The payment is intended for general operating and 2L+ OPSCC trial expenses. Inversagen AI was formed by GATC Health and Inversagen, which hold exclusive licence rights to senescence AI longevity technologies and BioAtla's conditionally active biologic (CAB) senescence and longevity technologies, respectively. The initial closing of the transaction will coincide with Inversagen AI's first financing round, anticipated by 30 January 2026. The remaining $35m is expected to close in the first quarter of 2026, aligned with the planned launch of the Oz-V registrational clinical study. Both tranches are subject to completion of financing and customary closing conditions. Upon completion of the transaction, Inversagen AI will hold a 35% ownership
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla (NASDAQ:BCAB) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating and a $4.00 price target on the stock.MarketBeat
- BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC) [Yahoo! Finance]Yahoo! Finance
- BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)GlobeNewswire
BCAB
Earnings
- 11/13/25 - Beat
BCAB
Sec Filings
- 2/11/26 - Form DEFM14A
- 2/9/26 - Form 8-K
- 2/6/26 - Form 8-K
- BCAB's page on the SEC website